These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33064728)

  • 1. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
    Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J
    PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
    Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
    JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing.
    Wang N; Parimi L; Liu H; Zhang F
    Am J Trop Med Hyg; 2017 May; 96(5):1014-1018. PubMed ID: 28167593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol.
    Krismawati H; Ferdiana A; Irwanto A; Budiawan T; Imaniar C; Wahyuni T; Singh P; Mieras L; Pongtiku A
    BMJ Open; 2022 May; 12(5):e057173. PubMed ID: 35545382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.
    Park HJ; Park JW; Kim SH; Choi SY; Kim HK; Jung CG; Yang MS; Kang DY; Cho MK; Kwon HS; Kang HR; Lee YW;
    Expert Opin Drug Saf; 2020 Oct; 19(10):1349-1356. PubMed ID: 32700588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
    Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
    Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions.
    Chen WT; Wang CW; Lu CW; Chen CB; Lee HE; Hung SI; Choon SE; Yang CH; Liu MT; Chen TJ; Fan WL; Su SC; Lin YY; Chang YC; Chung WH;
    J Invest Dermatol; 2018 Jul; 138(7):1546-1554. PubMed ID: 29458119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
    Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
    Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B*13:01 and the dapsone hypersensitivity syndrome.
    Zhang FR; Liu H; Irwanto A; Fu XA; Li Y; Yu GQ; Yu YX; Chen MF; Low HQ; Li JH; Bao FF; Foo JN; Bei JX; Jia XM; Liu J; Liany H; Wang N; Niu GY; Wang ZZ; Shi BQ; Tian HQ; Liu HX; Ma SS; Zhou Y; You JB; Yang Q; Wang C; Chu TS; Liu DC; Yu XL; Sun YH; Ning Y; Wei ZH; Chen SL; Chen XC; Zhang ZX; Liu YX; Pulit SL; Wu WB; Zheng ZY; Yang RD; Long H; Liu ZS; Wang JQ; Li M; Zhang LH; Wang H; Wang LM; Xiao P; Li JL; Huang ZM; Huang JX; Li Z; Liu J; Xiong L; Yang J; Wang XD; Yu DB; Lu XM; Zhou GZ; Yan LB; Shen JP; Zhang GC; Zeng YX; de Bakker PI; Chen SM; Liu JJ
    N Engl J Med; 2013 Oct; 369(17):1620-8. PubMed ID: 24152261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapsone hypersensitivity syndrome among leprosy patients in China.
    Tian W; Shen J; Zhou M; Yan L; Zhang G
    Lepr Rev; 2012 Dec; 83(4):370-7. PubMed ID: 23614255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal.
    Rao PN; Lakshmi TS
    Lepr Rev; 2001 Mar; 72(1):57-62. PubMed ID: 11355519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapsone hypersensitivity syndrome in a lepromatous leprosy patient--A Case Report.
    Gavilanes MC; Palacio AL; Chellini PR; Nery JA; Rego JG
    Lepr Rev; 2015 Jun; 86(2):186-90. PubMed ID: 26502691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan.
    Sheen YS; Chu CY; Wang SH; Tsai TF
    J Dermatolog Treat; 2009; 20(6):340-3. PubMed ID: 19954390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.
    Watanabe H; Watanabe Y; Tashiro Y; Mushiroda T; Ozeki T; Hashizume H; Sueki H; Yamamoto T; Utsunomiya-Tate N; Gouda H; Kusakabe Y
    J Dermatol Sci; 2017 Dec; 88(3):320-329. PubMed ID: 28870516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal hypersensitivity vasculitis associated with dapsone.
    Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Rabel-Filho OC; Martini-Filho D; Fontes CJ
    Am J Kidney Dis; 2005 Oct; 46(4):e51-3. PubMed ID: 16183407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.